← Back to Search

Diagnostic Test

Cancer Screening for Blood Clots (MVTEP2/SOME2 Trial)

N/A
Recruiting
Research Sponsored by University Hospital, Brest
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Unprovoked VTE is defined as the absence of any of the following predisposing factors: active malignancy (known malignancy, progressive and/or treated during the last 5 years) except for adequately treated basal or squamous cell carcinoma; Patients whose state of health suggests the presence of cancer at the time of diagnosis of VTE cannot be included in the protocol
Patients aged 50 years or older with a new diagnosis of first unprovoked proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) will be eligible to participate into the study.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 year of follow-up
Awards & highlights

MVTEP2/SOME2 Trial Summary

This trial found that VTE can be the earliest sign of cancer and that identifying occult cancers at the time of VTE diagnosis may lead to significant improvement of patients' care.

Who is the study for?
This trial is for people aged 50 or older who have had a blood clot (VTE) without any clear cause. They shouldn't have known clotting disorders, active cancer in the last 5 years, recent major surgery, paralysis, or been bedridden recently. Participants must be able to give consent and commit to follow-up appointments.Check my eligibility
What is being tested?
The study is testing two ways of screening for hidden cancers in patients with unexplained blood clots: standard limited cancer screening versus adding a special imaging test called FDG PET/CT that can find cancer.See study design
What are the potential side effects?
There may be some side effects from the FDG PET/CT scan such as allergic reactions to the tracer used in the test. However, these are generally rare and most people do not experience significant side effects.

MVTEP2/SOME2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My blood clot was not caused by cancer or any known risk factors.
Select...
I am 50 or older and have a new diagnosis of DVT or PE.
Select...
My blood clot was not caused by recent surgery or being bedridden.
Select...
My blood clot occurred without any known cause.
Select...
My blood clot was not caused by a previous clot.
Select...
My blood clot was not caused by recent severe leg immobility.

MVTEP2/SOME2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 year of follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 year of follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occult cancer missed by screening strategies
Secondary outcome measures
Additional tests
Cancer-related mortality
Cost effectiveness analysis
+4 more

MVTEP2/SOME2 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Limited cancer screening + FDG PET/CTExperimental Treatment1 Intervention
Limited screening + FDG PET/CT
Group II: Limited cancer screeningActive Control1 Intervention
Limited screening alone.

Find a Location

Who is running the clinical trial?

University Hospital, BrestLead Sponsor
511 Previous Clinical Trials
235,203 Total Patients Enrolled
Ministry of Health, FranceOTHER_GOV
371 Previous Clinical Trials
363,533 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,336 Previous Clinical Trials
25,749,832 Total Patients Enrolled

Media Library

Limited cancer screening (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04304651 — N/A
Blood Clot Research Study Groups: Limited cancer screening, Limited cancer screening + FDG PET/CT
Blood Clot Clinical Trial 2023: Limited cancer screening Highlights & Side Effects. Trial Name: NCT04304651 — N/A
Limited cancer screening (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04304651 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In how many locales is this investigation functioning?

"Numerous locations across Canada are recruiting participants, including the University of Calgary in Calgary, McMaster University in Hamilton, and the University of Manitoba in Winnipeg. Additionally, there are several other sites where patients may be enrolled."

Answered by AI
Recent research and studies
~514 spots leftby Sep 2026